Compare · MMM vs NEPH
MMM vs NEPH
Side-by-side comparison of 3M Company (MMM) and Nephros Inc. (NEPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MMM and NEPH operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MMM is the larger of the two at $80.24B, about 2180.3x NEPH ($36.8M).
- Over the past year, MMM is up 6.7% and NEPH is down 0.9% - MMM leads by 7.6 points.
- MMM has hit the wire 4 times in the past 4 weeks while NEPH has been quiet.
- MMM has more recent analyst coverage (25 ratings vs 0 for NEPH).
- Company
- 3M Company
- Nephros Inc.
- Price
- $153.89+0.07%
- $3.42-0.29%
- Market cap
- $80.24B
- $36.8M
- 1M return
- +7.08%
- +9.44%
- 1Y return
- +6.72%
- -0.87%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 0
3M Company
3M Company develops, manufactures, and markets various products worldwide. It operates through four business segments: Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. The Safety and Industrial segment offers personal safety products, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules to industrial, electrical, and safety markets. The Transportation and Electronics provides electronics, such as display materials and systems, electronic materials solutions; automotive and aerospace, and commercial solutions; advanced materials; and transportation safety products to transportation and electronic original equipment manufacturer customers. The Health Care segment offers medical and surgical supplies, skin health and infection prevention products, oral care, separation and purification sciences, health information systems, drug delivery systems, and food safety products to healthcare industry. The Consumer segment provides home improvement, home care, and consumer health care products, as well as stationery and office supplies to various consumers. This segment is also involved in the retail auto care business. It offers its products through various e-commerce and traditional wholesalers, retailers, jobbers, distributors, and dealers, as well as directly to users. 3M Company has a strategic collaboration with Merry Maids in residential cleaning sector; and collaborations with The Infectious Disease Research Institute and Duke Human Vaccine Institute to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2. The company was founded in 1902 and is headquartered in St. Paul, Minnesota.
Nephros Inc.
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company operates through three segments: Water Filtration, Pathogen Detection, and Renal Products. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company develops and sells water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. Nephros, Inc. was incorporated in 1997 and is headquartered in South Orange, New Jersey.
Latest MMM
- 3M Company filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- 3M Announces New Board Appointment
- SEC Form SD filed by 3M Company
- 3M Announces Upcoming Investor Event
- 3M Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Sweet Thomas W was granted 1,360 shares (SEC Form 4)
- Director Kereere Suzan was granted 1,360 shares, increasing direct ownership by 27% to 6,422 units (SEC Form 4)
- Director Fitterling James R was granted 1,360 shares (SEC Form 4)
- Director Brown Thomas K was granted 1,360 shares (SEC Form 4)
- Director Chow Anne H was granted 1,360 shares (SEC Form 4)
Latest NEPH
- Nephros Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Nephros Announces Financial Results for Quarter Ended March 31, 2026
- SEC Form 10-Q filed by Nephros Inc.
- Amendment: SEC Form 10-K/A filed by Nephros Inc.
- Nephros Schedules First Quarter 2026 Financial Results Conference Call
- Nephros Expands Strategic Focus in Greater New York Market with Dedicated Regional Leadership
- Nephros Expands Water Safety Capabilities With ASSE 12080 Certified Water Management Planning Expertise
- Nephros Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 4 filed by Banks Robert R. Jr.
- SEC Form 4 filed by Krandel Judy